EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Genetic Landscape of DMD Gene Mutations in Iranian Patients and the Applicability of Molecular Therapies

Ali Khanbazi, Farzane Zare Ashrafi, Masoumeh Akbari Kelishomi, Raziye Rezvani Rezvandeh, Maryam Azad, Fatemeh Ahangari, Mahsa Fadaee, Shima Dehdahsi, Mina Makvand, Banafsheh Salmani, Zohreh Vahidi, Mahdieh Kooshki und 21 weitere

Archives of Iranian Medicine · 01.03.2026 · 29 (3) · 156-164

DOI: 10.34172/aim.35359 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archives of Iranian Medicine, online erschienen am 01.03.2026. Verfasst von Ali Khanbazi und 32 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Mutations in the X-linked dystrophin gene ( DMD ) cause Duchenne (DMD) and Becker muscular dystrophies (BMD), severe and milder forms of inherited progressive muscle deterioration, for which genetic testing is essential to confirm diagnosis, genetic counseling, and eligibility for molecular therapies.

Objective

This study aimed to elucidate the pattern of DMD mutations in a large cohort of Iranian patients and assess the applicability of mutation-specific therapies.

Methods

We retrospectively analyzed 2162 individuals referred to the Kariminejad - Najmabadi Pathology & Genetics Center (KNPGC) for DMD mutation testing. The samples consisted of 1093 males for diagnostic testing, 946 females for carrier detection, and 123 fetuses for prenatal assessments. Most cases were first examined using multiplex ligation-dependent probe amplification (MLPA), with negative results further evaluated by next-generation sequencing (NGS) or Sanger sequencing.

Results

Among 1093 males tested for diagnostic purposes, 608 (55.63%) were positive for DMD mutations. Among these positive cases, 470 deletions (77.30%) and 81 duplications (13.32%) were identified. Point mutations were identified in 55 patients (9.05%), with nonsense and frameshift variants being the most prevalent. Mutations predominantly affected exons 44–55 (44.17%) and 3–27 (35.75%). Notably, 69.09% of point mutations were located within the proximal 40 exons of the gene. Additionally, DP427 isoforms were disrupted in all patients, while shorter isoforms (DP116, DP71) were rarely affected. Applicability of mutation-specific therapies indicated that 49.34% of patients could theoretically benefit from exon-skipping strategies, 29.60% were eligible for currently approved therapies, and 3.45% with nonsense mutations could benefit from a read-through therapy.

Conclusion

This study provides an overview of DMD mutations in a large cohort of patients referred for testing, highlighting mutation patterns and the potential applicability of molecular therapies.

Zitieren

APA

Khanbazi, A., Ashrafi, F. Z., Kelishomi, M. A., Rezvandeh, R. R., Azad, M., Ahangari, F., Fadaee, M., Dehdahsi, S., Makvand, M., Salmani, B., Vahidi, Z., Kooshki, M., Ahmadpour, A., Shiuokhi, E., Ghaderi, A., Tahmasebivand, M., Afroozan, F., Noudehi, K., Fatehi, F., …, & Najmabadi, H. (2026). Genetic Landscape of DMD Gene Mutations in Iranian Patients and the Applicability of Molecular Therapies. Archives of Iranian Medicine, 29(3), 156-164. https://doi.org/10.34172/aim.35359

Vancouver

Khanbazi A, Ashrafi FZ, Kelishomi MA, Rezvandeh RR, Azad M, Ahangari F, et al. Genetic Landscape of DMD Gene Mutations in Iranian Patients and the Applicability of Molecular Therapies. Archives of Iranian Medicine. 2026;29(3):156-164. doi:10.34172/aim.35359

BibTeX
@article{Khanbazi2026,
  author = {Khanbazi, Ali and Ashrafi, Farzane Zare and Kelishomi, Masoumeh Akbari and Rezvandeh, Raziye Rezvani and Azad, Maryam and Ahangari, Fatemeh and Fadaee, Mahsa and Dehdahsi, Shima and Makvand, Mina and Salmani, Banafsheh and Vahidi, Zohreh and Kooshki, Mahdieh and Ahmadpour, Atiyeh and Shiuokhi, Elmira and Ghaderi, Armita and Tahmasebivand, Mahsa and Afroozan, Fariba and Noudehi, Khadijeh and Fatehi, Fatemeh and Najafabadi, Shima Zamanian and Jafarnataj, Elahe and Nafissi, Shahriar and Habibi, Haleh and Taghdiri, Maryam and Ashtiani, Bahram Haghi and Zamani, Gholamreza and Fatehi, Farzad and Bakhshandeh, MohammadKazem and Parvini, Farshid and Jamali, Payman and Kahrizi, Kimia and Kariminejad, Ariana and Najmabadi, Hossein},
  title = {Genetic Landscape of DMD Gene Mutations in Iranian Patients and the Applicability of Molecular Therapies},
  journal = {Archives of Iranian Medicine},
  year = {2026},
  volume = {29},
  number = {3},
  pages = {156--164},
  doi = {10.34172/aim.35359}
}
Kostenlos starten →